Stay updated on Extension of AK002 in Eosinophilic Gastritis Clinical Trial

Sign up to get notified when there's something new on the Extension of AK002 in Eosinophilic Gastritis Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Extension of AK002 in Eosinophilic Gastritis Clinical Trial page

  1. Check
    yesterday
    No Change Detected
  2. Check
    2 days ago
    No Change Detected
  3. Check
    3 days ago
    No Change Detected
  4. Check
    4 days ago
    No Change Detected
  5. Check
    5 days ago
    Change Detected
    Summary
    The value of Revision has been updated from v2.8.0 to v2.8.1, indicating a recent revision in the content of the webpage.
    Difference
    0.1%
    Check dated 2024-06-13T21:10:16.000Z thumbnail image
  6. Check
    12 days ago
    Change Detected
    Summary
    The value on the webpage has changed from 7 to 8, indicating a recent update in the number of doses of AK002 given monthly for up to 26 doses in a Phase 2, open-label, extension study for patients with Eosinophilic Gastritis and/or Eosinophilic Duodenitis.
    Difference
    0.1%
    Check dated 2024-06-06T14:21:16.000Z thumbnail image
  7. Check
    27 days ago
    Change Detected
    Summary
    The 'Participation Criteria' section has been updated to include detailed eligibility criteria for participants, specifying requirements such as written informed consent and completion of a prior study. Previously, no information was provided in this section.
    Difference
    32%
    Check dated 2024-05-22T20:55:12.000Z thumbnail image
  8. Check
    49 days ago
    Change Detected
    Difference
    1%
    Check dated 2024-04-30T22:21:18.000Z thumbnail image

Stay in the know with updates to Extension of AK002 in Eosinophilic Gastritis Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Extension of AK002 in Eosinophilic Gastritis Clinical Trial page.